Skip to content
›

Named Clinical Research Center for TCM Rheumatic & Immune Diseases

On October 28th, Hebei Yiling Hospital held the unveiling ceremony for the “Shijiazhuang Clinical Research Center for Traditional Chinese Medicine (TCM) Rheumatic and Immune Diseases.” At the same time, plaques were awarded to five core constituent units, including Hebei Provincial Hospital of Traditional Chinese Medicine, and eleven network constituent units, including Jinzhou City Hospital of Traditional Chinese Medicine. This will further promote the construction of the hospital’s medical science and technology innovation system and enhance clinical medical research capabilities and the application of scientific and technological achievements. The recognition of this clinical research center was initiated and reviewed by the Shijiazhuang Science and Technology Bureau. Based at Hebei Yiling Hospital, the Shijiazhuang Clinical Research Center for TCM Rheumatic and Immune Diseases is the only TCM clinical research center among the five clinical research centers awarded this time.

According to reports, the Shijiazhuang Clinical Research Centers aim to promote innovation in clinical medical science and technology and the transformation of scientific and technological achievements. Hebei Yiling Hospital is a Grade-A tertiary TCM hospital and a national drug clinical trial institution. Its Rheumatology Department is a key TCM specialty designated by the Hebei Provincial Administration of Traditional Chinese Medicine, the host unit of the Rheumatic and Bone Disease Professional Committee of the Hebei Provincial Association of Traditional Chinese Medicine, the deputy chair unit of the Rheumatology Branch of the Hebei Association of Integrative Medicine, and a founding unit of the International Scleroderma Clinical and Research Collaboration Organization (inSCAR). The department has also established a clinical research and translational platform based on the collateral-disease theory. The Shijiazhuang Clinical Research Center for TCM Rheumatic and Immune Diseases, approved through application by the Rheumatology Department of Hebei Yiling Hospital, will further promote the construction of a clinical medical innovation system deeply integrating production, education, and research. This system is guided by TCM theory, led by medical institutions, and oriented towards clinical application of TCM, thereby realising the significant guiding value of TCM in the prevention and treatment of rheumatic and immune diseases. It will foster the transformation of research achievements with national influence and enhance the impact of integrative rheumatic and immune disciplines in Shijiazhuang.

Guo Gang, a renowned TCM physician in Shijiazhuang, Vice President of Hebei Yiling Hospital, and Director of the Second Rheumatology Department, has been engaged in the diagnosis and treatment of rheumatic and immune diseases for over 30 years. He currently serves as a standing committee member of the Rheumatology Professional Committee of the Chinese Association of Integrative Medicine, an academic advisory expert for the Beijing-Tianjin-Hebei Rheumatology Community, Chair of the Rheumatic and Bone Disease Professional Committee of Hebei Province, Deputy Chair of the Rheumatology Professional Committee of Hebei Association of Integrative Medicine, and inaugural executive committee member of the International Scleroderma Clinical and Research Collaboration Network (inSCAR). He pointed out that rheumatic immune diseases are a group of systemic diseases related to immunity, characterised by non-organ-specific inflammation. The rational application of TCM and Chinese herbal medicine in treatment can demonstrate unique advantages through its holistic approach and syndrome differentiation-based treatment.

For many years, the Rheumatology Department of Hebei Yiling Hospital has consistently adhered to the integration of traditional Bi disease theory and collateral-disease theory to guide the diagnosis and treatment of rheumatic immune diseases. It has validated TCM diagnostic and treatment protocols for key diseases under the guidance of collateral-disease theory, innovatively summarising and establishing the “Cold-Heat–Collateral Disease–Zang-Fu” syndrome differentiation system. This system is applied in the diagnosis and treatment of scleroderma and other diffuse systemic connective tissue diseases. The department has applied for scientific research projects and conducted clinical validation, with theoretical innovation driving breakthroughs in efficacy. Over 30 years since its establishment, the department has published over 100 papers in provincial-level and higher academic journals, authored four medical monographs, participated in two national new drug research fund projects, one National Natural Science Foundation project, one Ministry of Science and Technology national international cooperation special project, and nearly ten provincial-level research projects, winning six provincial and municipal awards.

Following the establishment of the Shijiazhuang Clinical Research Center for TCM Rheumatic and Immune Diseases at Hebei Yiling Hospital, the center will focus on major rheumatic and immune diseases to improve the diagnosis and treatment capabilities for difficult and complex cases. It will establish a biobank and clinical medical database for rheumatic and immune diseases, conduct randomized controlled trials of TCM treatments for these diseases, and carry out research such as clinical experience mining. Meanwhile, the center will actively integrate high-quality multidisciplinary resources from regional cooperative units to promote disciplinary integration and vigorously advance the construction of a collaborative network of units. Hebei Yiling Hospital will further strengthen management and services for the center, fully leveraging its role in disease diagnosis and treatment technology research, medical-research-industry collaborative innovation, clinical outcome transformation and promotion, academic exchange, and talent training, providing scientific and technological support for the medical development of Shijiazhuang and the construction of a Healthy Shijiazhuang.

— Article excerpted from Hebei News Network, November 9, 2023

Related reading